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REPORT
Crisponi Syndrome Is Caused by Mutations in the CRLF1 Gene
and Is Allelic to Cold-Induced Sweating Syndrome Type 1
Laura Crisponi,* Giangiorgio Crisponi,* Alessandra Meloni, Mohammad Reza Toliat,
Gudrun Nu¨rnberg, Gianluca Usala, Manuela Uda, Marco Masala, Wolfgang Ho¨hne, Christian Becker,
Mara Marongiu, Francesca Chiappe, Robert Kleta, Anita Rauch, Bernd Wollnik, Friedrich Strasser,
Thomas Reese, Cornelis Jakobs, Gerd Kurlemann, Antonio Cao, Peter Nu¨rnberg, and Frank Rutsch
Crisponi syndrome is a severe autosomal recessive condition that is phenotypically characterized byabnormal,paroxysmal
muscular contractions resembling neonatal tetanus, large face, broad nose, anteverted nares, camptodactyly, hyperther-
mia, and sudden death in most cases. We performed homozygosity mapping in ﬁve Sardinian and three Turkish families
with Crisponi syndrome, using high-density single-nucleotide polymorphism arrays, and identiﬁed a critical region on
chromosome 19p12-13.1. The most prominent candidate gene was CRLF1, recently found to be involved in the path-
ogenesis of cold-induced sweating syndrome type 1 (CISS1). CISS1 belongs to a group of conditions with overlapping
phenotypes, also including cold-induced sweating syndrome type 2 and Stu¨ve-Wiedemann syndrome.All these syndromes
are caused by mutations of genes of the ciliary neurotrophic factor (CNTF)–receptor pathway. Here, we describe the
identiﬁcation of four different CRLF1 mutations in eight different Crisponi-affected families, including a missense mu-
tation, a single-nucleotide insertion, and a nonsense and an insertion/deletion (indel) mutation, all segregating with the
disease trait in the families. Comparison of the mutation spectra of Crisponi syndrome and CISS1 suggests that neither
the type nor the location of the CRLF1 mutations points to a phenotype/genotype correlation that would account for
the most severe phenotype in Crisponi syndrome. Other, still-unknown molecular factors may be responsible for the
variable phenotypic expression of the CRLF1 mutations. We suggest that the syndromes can comprise a family of “CNTF-
receptor–related disorders,” of which Crisponi syndrome would be the newest member and allelic to CISS1.
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Crisponi syndrome (MIM 601378) is a severe autosomal
recessive condition described for the ﬁrst time in 1996 by
Giangiorgio Crisponi.1 Recently, Accorsi et al.2 and Nan-
nenberg et al.3 each reported a further case with the same
phenotype and suggested that the syndrome be named
after the author of the ﬁrst report. The disorder is evident
at birth and is characterized by marked contraction of the
facial muscles in response to tactile stimuli or during cry-
ing, with trismus and abundant salivation simulating a
tetanic spasm. Contractions of the oropharyngealmuscles
associated with absence of the swallowing reﬂex are also
observed. These contractions slowly disappear as the in-
fant calms. All patients described to date present facial
anomalies, including large face, chubby cheeks, broad
nose with anteverted nostrils, and bilateral camptodactyly
(ﬁg. 1). The clinical course is characterized by marked
sucking difﬁculties requiring nasogastric tube feeding.
Moreover, patients become hyperthermic, with core tem-
peratures of ∼38C accompanied by irregular febrile epi-
sodes of 142C, with age at onset ranging from birth to a
few weeks. In some patients, generalized seizures occur.
Most patients die within the ﬁrst months of life, during
hyperthermic episodes. In two of these cases, reduced lev-
els of g-aminobutyric acid (GABA) were noted in cerebro-
spinal ﬂuid,1,4 but the pathogenic relevance of this ﬁnding
is unclear. Surviving patients usually develop a severe pro-
gressive kyphoscoliosis (ﬁg. 1E) requiring corset therapy
or corrective surgery. We have also observed paradoxical
sweating after exposure to low ambient temperature in
some affected adolescents. On the basis of the appearance
of multiple affected siblings of both sexes in one family,
autosomal recessive inheritance is most likely. Phenotypic
overlap of Crisponi syndrome with Stu¨ve-Wiedemann
syndrome (SWS)/ Schwartz-Jampel type 2 syndrome (SJS2)
(MIM 601559)5–7 was discussed by Nannenberg et al.3 This
syndrome was recently linked to mutations in the LIFR
gene.8 However, bowing of the long bones, themost prom-
inent feature of SWS, was never observed in patients with
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Figure 1. Typical clinical features of Crisponi syndrome. 1, Subject CS07. 2, Subject CS10. 3, Subject CS14. 4, Subject CS03. A–D,
Facial expression at different ages, from birth to present. E, Front and back views, at the present time. Note scoliosis and limited
extension of elbows. F, Subjects’ hands. Note consistent camptodactyly. 5, Subject CS37, aged 14 mo. Note perioral muscular contractions
(A) and camptodactyly (B and C). 5D and 5E, Subject CS42, aged 13 years. Note thorakolumbal scoliosis (D) and camptodactyly (E).
5F, Subject CS41, aged 14 years. Note camptodactyly.
Crisponi syndrome. Therefore, having excluded linkage
to LIFR by microsatellite-marker studies (data not shown),
we started a positional cloning effort in eight unrelated
families from Sardinia and Turkey, to identify the causa-
tive gene for Crisponi syndrome (ﬁg. 2A and 2B). The
study was approved by the Research Ethics Committee of
the Azienda Sanitaria Locale 8 (ASL8), Cagliari, and by
the Research Ethics Committee of Mu¨nster University
Hospital.
The phenotype and the clinical course of Crisponi syn-
drome is exempliﬁed by the following case report: subject
CS07 (ﬁg. 1 rows 1A–F), the male proband of family 2 (F2)
(ﬁg. 2), was born at 38 wk of gestation as the ﬁrst child
of nonconsanguineous Sardinian parents. Birth weight
was 3,130 g (50th percentile) and length was 48 cm (50th
percentile). Right after birth, he was unable to suck and
had massive spasms of the mimic muscles during crying,
with abundant salivation. Minor anomalies included
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Figure 2. A and B, Pedigrees of the ﬁve Sardinian and three Turkish families. A blackened symbol indicates an affected individual
with Crisponi syndrome; an unblackened symbol indicates an unaffected individual; a dot in the center of a symbol indicates an obligate
carrier; a blackened symbol with slash indicates a deceased affected individual; and an asterisk (*) indicates that a sample from the
subject was analyzed in the present study. E and E indicate the presence or absence, respectively, of mutations, which are indicated
by number(s) in parentheses and are described in panel C. In families F1 and F4, the probands CS03 and CS14 are compound heterozygous.
C, CRLF1 sequence analysis. Electropherograms are shown for each of the four mutations found in the present study: heterozygous
(middle) and homozygous (bottom) compared with wild type (top).
camptodactyly and a broad nose with anteverted nostrils.
An exaggerated response to noise and tactile stimuli, with
spasmodic contractions of the face, jaw, and neck muscles
and opisthotonus, was noted. Frequent contractions of the
oropharyngeal muscles associated with absence of the
swallowing reﬂex required nasogastric tube feeding. Early
in the neonatal period, the patient developed continuous
hyperthermia unrelated to infectious agents, dyspnea, ap-
nea spells, and cyanosis during crying. Febrile episodes
disappeared after the 1st year of life, whereas feeding dif-
ﬁculties persisted. At age 6 years, episodic sweating began.
The sweating commenced at the upper lip and eyebrows
and spread to the thorax and the palms of both hands,
which then became cold and cyanotic. Sweating was pro-
Table 1. Overview of the Phenotype of Patients Investigated for CRLF1 Mutations
Family (Consanguinity),
Geographic Origin,
and Patient Born Sex
Age at
Death Scoliosis Seizures
Age at Onset of
Paradoxical
Sweating
(years)
Abnormal
Clinical Course DNA Sequence VariantEEGa Karyotype Amino Acid Change
1 ():
Sardinia:
Brother 1971 M 5 wk    NE NE NE NE
Brother 1973 M 12 wk    NE  NE NE
Sister 1975 F 8 wk    NE  NE NE
CS03 1979 F Alive   Puberty   High-arched palate, developmental delay, and nasogastric
tube feeding for 3 years
c.226TrG c.676-677insA p.Trp76Gly p.Thr226AsnfsX104
2 ():
Sardinia:
CS07 1998 M Alive   6  NE Heat intolerance c.676-677insA p.Thr226AsnfsX104
3 ():
Sardinia:
Brother 1993 M 12 wk      NE NE
CS10 1995 F Alive   9   Heat intolerance and erosive keratitis c.676-677insA p.Thr226AsnfsX104
4 ():
Sardinia:
CS14 1993 F Alive   9  NE Suspected anhydrotic ectodermal dysplasia and erosive
keratitis
c.226TrG c.676-677insA p.Trp76Gly p.Thr226AsnfsX104
5 ():
Sardinia:
CS17 2004 F Alive      Heat intolerance; camptodactyly resolved at age 2 years c.226TrG p.Trp76Gly
6 ():
Turkey:
CS21 2002 F Alive      Speech delay, erosive keratitis, and gastrostomy tube feed-
ing for 18 mo
c.1102ArT p.Lys368X
7 ():
Turkey:
CS37 2003 M 30 mo      High-arched palate, gastroesophageal reﬂux, low CSF GABA
levels,b and gastrostomy tube feeding for 2 years
c.708-709delCCinsT p.Pro238ArgfsX6
8 ():
Turkey:
CS41 1990 M Alive   10   Nasogastric tube feeding for 10 mo and speech delay c.708-709delCCinsT p.Pro238ArgfsX6
CS42 1991 F Alive   7   Nasogastric tube feeding for 12 mo and speech delay c.708-709delCCinsT p.Pro238ArgfsX6
NOTE.—All subjects had perioral contractions, camptodactyly, hyperthermia, and feeding difﬁculties. NEpnot examined; a minus sign ()punaffected or normal result.
a Electroencephalogram.
b Levels of GABA in cerebrospinal ﬂuid (CSF) at age 17 mo: total GABA 3.1 mmol/liter (normal range 4.2–13.4 mmol/liter), free GABA 0.011 mmol/liter (normal range .017–.067 mmol/liter).
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Figure 3. Mapping of a locus for Crisponi syndrome on 19p12-13.1. Multipoint linkage analysis was performed using 250K SNP genotype
data from nine affected and three unaffected children. The program MERLIN was used with the recently implemented LD-modeling
option, to avoid inﬂated LOD scores.13 A, Under the assumption of locus heterogeneity (i.e., HLOD calculation), the highest LOD scores
were obtained for chromosome 19 markers, with a maximum LOD score of 4.74 at 46.77 cM, according to the deCODE map. B,Magniﬁcation
of chromosome 19. The red line indicates the position of the CRLF1 gene.
voked by low ambient temperature and by increased hu-
midity. The child could not tolerate heat, lived in a house
with air conditioning, and walked barefoot. During a
sweat test, at 22C ambient temperature, localized sweat-
ing around the eyebrows and the lips was noted, followed
by mild sweating on the shoulders.
The phenotypes of the patients in families 1 and 4 were
summarized in the original article by Crisponi, and “fam-
ily 1” and “family 4” in the present study refer to family
E and family K, respectively, in the work of Crisponi.1 We
noted that the Sardinian family 4 described in our report
is also identical to family 1 in the recent report by Da-
goneau et al.9(in this issue) We include an overview of the phe-
notype and follow-up data from these patients and from
an additional eight patients of six new families with Cris-
poni syndrome (table 1). To identify the underlying dis-
ease gene, we performed a genome scan to identify ho-
mozygous regions shared by the probands of the different
families. The parents of the Sardinian patients were not
known to be related, but several grandparents had been
born in the same rural area, raising the possibility of a
distant consanguineous loop. Moreover, the relatively
high incidence of Crisponi syndrome among Sardinians
strongly suggested a founder effect in this isolated pop-
ulation. Therefore, we introduced consanguineous loops
into all eight families (conservatively assigned as second-
cousin parents for those of unknown consanguinity),with
either one or two offspring, when performing the linkage
analysis. We have used this approach successfully in pre-
vious positional cloning projects in which also a high pro-
portion of consanguineous families was only assumed but
not proven a priori.10,11 Here, we genotyped DNA samples
from nine affected and three unaffected children of
known and suspected consanguineous unions, using the
Affymetrix GeneChip Human Mapping 250K Sty Array.
For this array, the StyI restriction enzyme was used as an
initial step in sample preparation (Affymetrix protocol).
Up to ∼238,000 SNPs with an average spacing of ∼12 kb
were interrogated. Genotypes were called using the
GeneChip DNA Analysis Software (GDAS v. 3.0 [Affyme-
trix]). We veriﬁed sample sexes by counting heterozygous
SNPs on the X chromosome. Relationship errors were eval-
uated with the help of the programGraphical Relationship
Representation.12 Non-Mendelian errors were identiﬁedby
using the program MERLIN,13 and unlikely genotypes for
related samples were deleted. Parametric linkage analysis
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Figure 4. Haplotype analyses on chromosome 19p12-13.1. Homozygous regions that are supposed to be identical by descent in each
family are shown in red. The position of the CRLF1 gene is indicated by a boxed SNP trio representing an intragenic SNP (rs8107912)
and the two nearest ﬂanking SNPs (rs7258589 and rs7256751) that are tiled on the 250K Sty array from Affymetrix. A critical interval
of 1.45 Mb may be deﬁned by the overlap of homozygous regions (solid arrows). The broken-line arrows deﬁne less reliable borders if
it is decided beforehand that either F1 or F2 is homozygous at the disease-gene locus.
was performed with the programs ALLEGRO14 and a new
version of MERLIN that allows for marker clustering to
compensate for linkage disequilibrium (LD) between ad-
jacent markers.13,15 Haplotypes were reconstructed by a
modiﬁed version of the program GENEHUNTER 2.116,17
and were presented graphically with HaploPainter.18 All
data handling was performed using the graphical user in-
terface ALOHOMORA.19 Linkage analysis under the as-
sumption of locus heterogeneity (i.e., heterogeneity LOD
[HLOD] score) revealed a single maximum LOD score of
4.74 for the region 19p12-13.1 (ﬁg. 3). On the basis of the
haplotype data from patients with extended homozygos-
ity, this interval is delimited by SNP markers rs2023878
and rs2023414 and comprises ∼1.5 Mb, with CRLF1 (cy-
tokine receptor–like factor 1) as the most promising po-
sitional candidate (ﬁg. 4). CRLF1 was still located in the
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Table 2. CRLF1 Primers and Conditions for Genomic PCR
Exon
Primer Sequence
(5′r3′)
Size
(bp)
Temperature
(C)Forward Reverse
1a TTAGCGCCTTGTCAATTCGGC TGTTCCCCGGCCGTCCAGG 394 60
2 GACAATCATTAACAGCGTC AGTGTGCCCACAGCTCATCC 507 54
3 GGAGATCGAGTCACCAGCCTC GGCAGCCTCAGGGTGCAGAC 441 68
4 CTTGACCAACGCGGACCCT ACTTACCTACCTTCCCTCTG 456 60
5 ACAGAGGCAGGTTCCATC CAGGAGGTCTGGTTGCTCAC 250 60
6 CTACCGAGTGGAGGACAGTG TATGCGACAGAATGAGGCCG 421 60
7a TCGGTCCTTGAGAAACGGG TTGGAGCAGTACGCGTGC 252 60
8a AGCTCAAGCAGTTCCTGG GGGTGTGAACAAGACCTGC 377 56
9 GGACAGGACACGAATGAAGC CATTAAGACGCCTCACATTCCC 518 62
NOTE.—PCR was performed in 25-ml ﬁnal volume, with 6 ng of genomic DNA, .64 mM
dinucleotide triphosphate, .16 pmol of each primer, and .75 U Taq polymerase
(Invitrogen).
a Requires 1M betaine (Sigma-Aldrich).
critical interval of ∼700 kb when a less conservative def-
inition was used and the bottom end of the short ho-
mozygous segment of patient CS07 of F2 was considered
for border determination. Only two patients (from fami-
lies F1 and F4) did not show a homozygous segment in
this narrow interval, suggesting either a compound het-
erozygous status or locus heterogeneity.
CRLF1 was considered the most prominent candidate
gene because it was recently found to be involved in the
pathogenesis of cold-induced sweating syndrome type 1
(CISS1 [MIM 272430]), which shows some overlapping
features with Crisponi syndrome as well as with SWS/
SJS2.20,21 CISS1 was ﬁrst described by Sohar et al.22 in two
Israeli sisters, and three other cases were subsequently re-
ported by Knappskog et al.20 and by Hahn et al.21 CISS1
is characterized by feeding difﬁculties during infancy, dys-
morphic features such as high-arched palate, low-set ro-
tated ears, depressed nasal bridge, ﬂexion deformities of
elbows and ﬁngers, and kyphoscoliosis. In addition, af-
fected patients experienced profuse sweating, induced by
cold ambient temperature, on their back and chest. These
features are also present in a similar although variable
manner in those patients affected by Crisponi syndrome
who survived to adolescence (see table 1).
Another form of cold-induced sweating syndrome (i.e.,
CISS2 [MIM 610313]) is known to be caused by mutations
in the CLCF1 (cardiotrophin-like cytokine factor 1) gene
on chromosome 11q13.3. Only one case has been reported
in the literature thus far, by Rousseau et al.23 The clinical
phenotype of both CISS1 and CISS2 is extremely similar,
although variable.
Using speciﬁc primers (see table 2), we performed direct
sequencing of the nine coding exons and surrounding in-
tronic regions of CRLF1 (GenBank accession number
NM_004750) in all our patients. We identiﬁed homozy-
gous and compound heterozygous mutations in the
CRLF1 gene in all affected individuals from all families,
and four mutations accounted for all mutant alleles. Mu-
tation types included one missense mutation, a single-
nucleotide insertion, a nonsense mutation, and an indel
mutation (see ﬁg. 2C and table 1 for details). By sequenc-
ing themutated exons in all the available familymembers,
we conﬁrmed that the mutations cosegregated with the
disease trait (ﬁg. 2A and 2B).
The CRLF1 protein (GenBank accession number
NP_004741) has a domain structure that includes a signal
sequence (positions 1–37) followed by an Ig-like C2-type
N-terminal domain (positions 38–131), two consecutive
ﬁbronectin III–like domains (positions 134–229 and 234–
334), and a C-terminal domain (positions 335–422). For
the ﬁrst three domains, homologous proteins have known
structures: for the Ig-like domain, the highest sequence
homology is found with a corresponding domain of the
neural cell adhesion molecule (NCAM [Protein Data Bank
{PDB} code 1EPF]); for the two ﬁbronectin domains, high
homology is seen with human prolactin receptor (PDB
code 1BP3). The C-terminus shows no homology to
known functional domains.24 The WSEWS motif at posi-
tion 327 is probably needed for correct folding and do-
main orientation of the protein.25
In all Sardinian families except family 5, the mutation
c.676-677insA was found. This mutation results in a thre-
oninerasparagine change at position 226, followed by a
frameshift, which leads to the deletion of a complete ﬁ-
bronectin domain as well as the C-terminal domain
(p.T226NfsX104) (ﬁg. 5A). Subjects CS07 and CS10 were
both homozygous for this mutation, whereas subjects
CS03 and CS14 were compound heterozygotes for
p.T226NfsX104 and the missense mutation c.226TrG.
This mutation results in a tryptophanrglycine substitu-
tion at position 76 of the Ig-like domain (p.W76G) (ﬁg.
5A). An inspection of the corresponding positions within
the structure of NCAM shows that tryptophan 76 is likely
buried within the molecule (ﬁg. 5C), and a substitution
by glycine would be expected to result in a loss of tight
internal side-chain arrangement and, thus, in a consid-
erable decrease in stability. The W76 is strictly conserved
within CRLF1 homologous proteins from different organ-
isms, as seen from a sequence alignment for the homol-
ogous sequences from mouse, zebraﬁsh, pufferﬁsh, and
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Figure 5. Positions of mutations in the CRLF1 gene and the CRLF1 protein. A, Intron/exon arrangement of the gene (dark shaded
areas are the 3′ and 5′ UTRs) and domain (dom.) arrangement of the protein (light shaded area: WSXWS consensus sequence of the
type I cytokine receptor family); red indicates mutations described in the present report; black indicates mutations described by
Knappskog et al.20 and Hahn et al.,21 gray indicates known polymorphisms, and pale red indicates the nonpathogenic variant described
in the present report. B, Multiple-sequence alignment for CRLF1 homologues and position of missense mutations within the Ig-like
domain. Conserved residues at the mutated positions are indicated in blue. Mouse (Mus musculus): Crlf1 (Q9JM58); zebraﬁsh (Brachydanio
rerio): protein Zgc:91992 (Q6D628); pufferﬁsh (Tetraodon nigriviridis): class I helical cytokine receptor number 1 (Q6UAQ5); X. laevis
(African clawed frog): GP130p1 (O57519). C, Schematic representation of the CRLF1 Ig-like domain homologous structure from NCAM.
Equivalent positions of the mutated residues (W76 and R89 in CRLF1, together with D112, most probably involved in a salt bridge with
R89) are shown in space-ﬁlling representation. The ﬁgure was drawn with ViewerPro 4.2 (ACCELRYS).
Xenopus laevis (ﬁg. 5B). The p.W76G missense mutation
was present homozygously in subject CS17 and was as-
sociated with a severe phenotype as severe as observed
with other truncating mutations found in Crisponi syn-
drome. Thus, two pathogenicCRLF1mutations were iden-
tiﬁed in the Sardinian families, suggesting potential foun-
der effects.
In the father and the unaffected child of family 4, we
detected the nucleotide change c.266GrA on one allele,
which predicts the amino acid change p.R89H. This al-
teration was found in trans with the deleterious mutation
c.226TrG/p.T226Nfs104X in the father. Because the fa-
ther did not present any symptoms of Crisponi syndrome,
we assumed that p.R89H was nonpathogenic. Arginine 89
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Figure 6. Family of CNTF-receptor–pathway related disorders. A, Phenotypic overlap of Crisponi syndrome, CISS1, CISS2, and SWS/
SJS2. B, CNTF-receptor complex, composed of gp130, LIFRb, and CNTFRa, required for binding CRLF1/CLCF1, which activates downstream
signal–transduction events, including phosphorylation of STAT3. Black lines link each protein to the corresponding related disorder.1–
8,20–22 (See also the London Medical Databases Web site.)
may form a salt bridge with aspartate 112, as inferred from
the NCAM structure (ﬁg. 5C), but this salt bridge is ex-
posed to the solvent and is also not completely conserved
in the four CRLF homologous sequences (ﬁg. 5B); it is thus
probably less important for a stable fold. The nucleotide
change c.266GrA was not reported elsewhere as a se-
quence variant, but it was also present in heterozygous
form in two of 192 unrelated Sardinian controls.
In the Turkish families, we detected a homozygous indel
mutation c.708-709delCCinsT in subjects CS37 (family 7)
and CS41 and CS42 (family 8), which leads to a frameshift
in the second ﬁbronectin type III domain (p.P238RfsX6)
(ﬁg. 5A). The fathers of the affected probands from these
two families originated from the same town in eastern
Turkey, again suggesting a common founder effect in this
instance. In family 6, the homozygous nonsensemutation
c.1102ArT was detected in subject CS21, resulting in a
prematurely terminated, truncated protein (p.K368X) (ﬁg.
5A). Parental heterozygosity was proved for the respec-
tive mutations in all the families. All four identiﬁed mu-
tations were screened in two panels of ethnicallymatched
control individuals (192 Sardinian and 152 Turkish). We
found one heterozygous carrier for p.W76G, one hetero-
zygote for p.T226Nfs104X, and two heterozygotes for
p.R89H. This carrier frequency is in line with the relatively
high incidence of Crisponi syndrome in the Sardinian
population.
Whereas the expression of the phenotype was quite sim-
ilar in the Sardinian families presenting with identical
CRLF1 mutations (mutations in family 1 identical to that
in family 4 and mutation in family 2 identical to that in
family 3), we observed variable expression of the phe-
notype in subject CS37 from family 7 and subjects CS41
and CS42 from family 8, all carrying the same nonsense
mutation. Whereas subject CS37 of family 7 had severe
dystonia, extreme feeding difﬁculties, gastroesophageal re-
ﬂux, persistent hyperthermia, and recurrent attacks of per-
iorbicular spasms before he died at age 30 mo, the clinical
course of the affected siblings of family 8 (subjects CS41
and CS42) was relatively mild. Their initial symptoms
gradually resolved during their 2nd year, and scoliosis and
paradoxical sweating started only after several years.
By demonstrating mutations in CRLF1 in patients with
Crisponi syndrome, we were able to prove allelism to
CISS1. Although present in the same gene, the different
mutations associated with CISS1 have been reported to be
associated with a phenotype less severe than that of Cris-
poni syndrome. In a more recent study, Dagoneau et al.9(in
this issue) reported independently that CRLF1 mutations ac-
count for both Crisponi syndrome and CISS1. Dagoneau
et al.9 suggested that nonsense mutations are associated
with the severe neonatal manifestations of Crisponi syn-
drome and that missense mutations are associated with
late-onset CISS1.9 In contrast to their observations, we
found no obvious genotype/phenotype correlation for
type or site of action of CRLF1 mutations in patients with
Crisponi syndrome or CISS1. In particular, we found a
homozygous missense mutation—namely, c.226TrG—in
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the proband of family 5, which was associated with the
most severe phenotype of Crisponi syndrome. Distinc-
tions are further complicated by the frequent presence of
combinations of different mutations in some cases of each
syndrome, with a considerable overlap of resulting symp-
toms between CISS1 and Crisponi syndrome (ﬁg. 6), in-
cluding feeding difﬁculties in infancy, cold-inducedsweat-
ing, and scoliosis in adolescence.
CRLF1 protein is involved in the ciliary neurotrophic
factor (CNTF)–receptor pathway, which is important for
both development and maintenance of the nervous sys-
tem.26 The stable secreted complex of CRLF1 and CLCF1
forms a ligand for CNTFRa, which, along with gp130
and LIFR, compose the CNTF-receptor complex.27 CRLF1/
CLCF1 binding to CNTFRa leads to dimerization of gp130/
LIFR, which in turn induces downstream signaling events,
including activation of the Janus kinase 1/STAT3 path-
way.28 In a mouse model, ablation of the CRLF1 gene sug-
gestively leads to inability to suck, and the mice die of
starvation shortly after birth, with their stomachs devoid
of milk.29 CRLF1 and CLCF1 are cytokines expressed in
sweat-gland tissue, and, currently, this complex is one of
the most likely candidates for the target derived sweat-
gland cholinergic differentiation factor.30 Therefore, it is
likely that, in Crisponi syndrome as well as in CISS1 and
CISS2, peripheral sudomotor functions are affected in a
comparable way, to cause the observed paradoxical sweat-
ing. In addition to sweat glands, there are at least two
different targets that are innervated by cholinergic sym-
pathetic neurons: the vasculature in skeletal muscle and
the periosteum.31 Asmus et al.32 demonstrated that im-
mature osteoblasts release soluble factor(s) of the neuro-
poietic cytokine family that induce cholinergic differen-
tiation in sympathetic neurons. Both the sweat-gland
factor and the periosteal factor(s) signal throughLIFRb and
are members of the neuropoietic cytokine family that is
still incompletely deﬁned. It would be critical to determine
whether CRLF1 is the long-sought cholinergic differenti-
ation factor that alters the transmitter properties of sym-
pathetic innervation of sweat glands and the periosteum
during development. Moreover, because the CNTF recep-
tor has different ligands but a common downstream sig-
naling pathway, the phenotypic overlap of CISS1/Crisponi
syndrome, CISS2, and SWS/SJS can be rationalized (ﬁg. 6).
We have shown allelism between Crisponi syndrome and
CISS1, although it remains openwhether these are distinct
clinical entities or a single disorder with variable degree
of phenotypic expression. In the present study, no obvious
genotype/phenotype correlation was observed for type or
localization of CRLF1 mutations in patients with Crisponi
syndrome or CISS1. Consequently, we suggest that other,
still-unknown molecular defects or variants could be re-
sponsible for the variable phenotypic expression of the
CRLF1 mutations.
In summary, we identiﬁed the molecular basis of Cris-
poni syndrome and found four different disease-causing
mutations in CRLF1 in ﬁve Sardinian and three Turkish
families. Furthermore, our ﬁndings demonstrate allelism
of Crisponi syndrome and CISS1. Although differences in
the severity of the two disorders exist, there is considerable
phenotypic overlap between both syndromes and simi-
larity to other syndromes related to the CNTF receptor
(i.e., CISS2 and SWS/SJS2). We therefore propose a new
syndrome family, called “CNTF receptor–related disor-
ders,” of which Crisponi syndrome would be the newest
member.
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